Press Enter to search · ESC to close

US Stocks

Eli Lilly’s Foundayo Meets Primary Endpoint in Late-Stage Sleep Apnea Trial

Eli Lilly said its oral weight-loss drug Foundayo significantly reduced breathing interruptions during sleep in obese adults with moderate-to-severe obstructive sleep apnea, meeting the primary goal of a late-stage clinical trial. At week 52, Foundayo cut breathing interruptions by up to 44% on average, as measured by the diagnostic scale used to assess sleep apnea severity. Obstructive sleep apnea is a disorder in which the upper airway repeatedly collapses during sleep, lowering blood oxygen and disrupting breathing.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback